[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342008-105":59,"doc-detail-342008-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","matched-three-dimensional-organoids-and-two-dimensional-cell-lines-of-melanoma-brain-metastases-mirror-response-to-targeted-molecular-therapy-research-findings","Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy - Research findings","","Metastatic melanoma brain metastasis remains difficult to treat, and existing preclinical models limit evaluation of therapeutic response. The study develops surgically eXplanted organoids (SXOs) from melanoma brain metastasis tissue using a minimally processed, three-dimensional culture approach without an artificial extracellular scaffold, alongside matched patient-derived two-dimensional cell lines. Generated organoids retain key histological and marker features and show sensitivity to BRAF and MEK inhibitors, supporting improved translational relevance and microenvironment studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/matched-three-dimensional-organoids-and-two-dimensional-cell-lines-of-melanoma-brain-metastases-mirror-response-to-targeted-molecular-therapy-research-findings/342008/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/matched-three-dimensional-organoids-and-two-dimensional-cell-lines-of-melanoma-brain-metastases-mirror-response-to-targeted-molecular-therapy-research-findings/342008.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What challenge does melanoma brain metastasis present in treatment?","Question",{"text":112,"@type":113},"Melanoma brain metastasis is a significant treatment challenge, with less durable responses to systemic targeted therapy in progressive CNS disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are the surgically eXplanted Organoids (SXOs) prepared in this study?",{"text":117,"@type":113},"MBM SXOs are created as ex vivo, three-dimensional cultures from primary tissue with minimal processing, avoiding an artificial extracellular scaffold and incorporating techniques for organoid establishment.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapies do the matched SXOs and cell lines respond to?",{"text":121,"@type":113},"Matched SXOs and patient-derived cell lines demonstrate sensitivity to BRAF and MEK inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342008,1790196766,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMatched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy  \nWilliam H. Hicks1,2, Lauren C. Gattie1,2, Mohamad El Shami1,2, Jeffrey I. Traylor3,4, Diwakar Davar2, Yana G. Najjar2, Timothy E. Richardson5, Samuel K. McBrayer3,6,7 & Kalil G. Abdullah1,2,8􀀍  \nDespite advances in the treatment paradigm for patients with metastatic melanoma, melanoma brain metastasis (MBM) continues to represent a significant treatment challenge. The study of MBM is limited, in part, by shortcomings in existing preclinical models. Surgically eXplanted Organoids (SXOs) are ex vivo, three-dimensional cultures prepared from primary tissue samples with minimal processing that recapitulate genotypic and phenotypic features of parent tumors without an artificial extracellular scaffold. MBM SXOs were created by a novel protocol incorporating techniques for establishing glioma and cutaneous melanoma organoids. A BRAFV600K-mutant and BRAF-wildtype MBM sample were collected directly from the operating room. Organoids were cultured in an optimized culture medium without an artificial extracellular scaffold. Concurrently, matched patient-derived cell lines were created. Organoid growth was observed within 3–4 weeks, and MBM SXOs retained histological features of the parent tissue, including pleomorphic epithelioid cells with abundant cytoplasm, large nuclei, focal melanin accumulation, and strong SOX10 positivity. After sufficient growth, organoids could be manually parcellated to increase the number of replicates. Matched SXOs and cell lines demonstrated sensitivity to BRAF and MEK inhibitors. Further study using SXOs may improve the translational relevance of preclinical studies and enable the study of the metastatic melanoma tumor microenvironment.  \nKeywords Metastatic melanoma, Organoids, Melanoma brain metastasis, Preclinical cancer model  \nMelanoma brain metastasis (MBM) represents a significant treatment challenge1. While combinatorial systemic targeted therapy in some subtypes has shown reasonable control rates in extracranial tumor burden, this treatment regimen has produced a less durable response in progressive central nervous system (CNS) disease2–4. The recent CheckMate 204 trial demonstrated concordant intracranial and extracranial benefits with combined immune checkpoint inhibitors; however, further study is needed to assess optimal therapy regimens, particularly in symptomatic MBM5,6. The decreased effectiveness of systemic targeted therapy to brain metastases has been thought to be related to poor blood-brain barrier penetration, the unique brain-tumor interface, and immune considerations ofthe brain-tumor immune microenvironment (TIME)7–9. While these interactions are critical to  \n1Department of Neurological Surgery, University of Pittsburgh, 200 Lothrop St, Pittsburgh, PA 15213, USA.  \n2Hillman Comprehensive Cancer Center, University of Pittsburgh Medical Center, 5115 Centre Ave, Pittsburgh, PA 15232, USA. 3Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75235, USA. 4Department of Neurological Surgery, University of Texas Southwestern Medical Center, 5303 Harry Hines Blvd, Dallas, TX 75390, USA. 5Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Ave, New York, NY 10029, USA. 6Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 7Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 8Department of Neurological Surgery, University of Pittsburgh Medical Center Hillman Cancer Center, 5150 Centre Avenue, Suite 430, Pittsburgh, PA 15232, USA. 􀀍 email: [abdullahkg@upmc.edu](abdullahkg@upmc.edu)  \n[www. nature.com/scientificreports/](www. nature.co","cbCaioOYlMbVD11m","https://ap.wps.com/l/cbCaioOYlMbVD11m","pdf",2418726,"English","# Background\n## Limitations of current models\n# Study approach\n## Surgically eXplanted Organoids (SXOs)\n## Matched patient-derived cell lines\n# Key findings\n## Histological retention and marker positivity\n## Drug sensitivity to BRAF and MEK inhibitors\n# Implications","[{\"question\":\"What challenge does melanoma brain metastasis present in treatment?\",\"answer\":\"Melanoma brain metastasis is a significant treatment challenge, with less durable responses to systemic targeted therapy in progressive CNS disease.\"},{\"question\":\"How are the surgically eXplanted Organoids (SXOs) prepared in this study?\",\"answer\":\"MBM SXOs are created as ex vivo, three-dimensional cultures from primary tissue with minimal processing, avoiding an artificial extracellular scaffold and incorporating techniques for organoid establishment.\"},{\"question\":\"What therapies do the matched SXOs and cell lines respond to?\",\"answer\":\"Matched SXOs and patient-derived cell lines demonstrate sensitivity to BRAF and MEK inhibitors.\"}]","Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy - Research findings | PDF",1790044730,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e41d48c3f9a0f2c46a1d2f6184f157e8.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbed1112243a1046d34815efcdaf57d4.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/305b137b31909f9fc35e237ba64c6e01.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d30b6a0515efd39653224c9f07ffde6.webp",980,1287]